[{"orgOrder":0,"company":"Procaps Group","sponsor":"BDR Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"LUXEMBOURG","productType":"Undisclosed","year":"2023","type":"Agreement","leadProduct":"Undisclosed","moa":"Tyrosine kinase","graph1":"Oncology","graph2":"Undisclosed","graph3":"Procaps Group","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"Procaps Group \/ BDR Pharmaceuticals","highestDevelopmentStatusID":"1","companyTruncated":"Procaps Group \/ BDR Pharmaceuticals"}]

Find Clinical Drug Pipeline Developments & Deals by Procaps Group

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
filter

Year

filter

DEALS // DEV.

filter

Country

filter
Sponsor
filter

Therapeutic Area

filter

Study Phase

filter

Deal Type

filter

Product Type

filter

Dosage Form

filter

Lead Product

filter

Target

Therapeutic Area by Lead Product

ForexGraph

Study Phase by Lead Product

ForexGraph

Company by Lead Product

ForexGraph

Top Deals by Deal Size (USD bn)

ForexGraph

01

Peptide Therapy Summit
Not Confirmed
Peptide Therapy Summit
Not Confirmed

Details : Under the agreement, Procaps will be responsible for registration, branding, marketing and commercialization of 27 oncology molecules for Latin America, including 20 TKIs (Tirosyne Kinase Inhibitors).

Product Name : Undisclosed

Product Type : Undisclosed

Upfront Cash : Undisclosed

July 09, 2023

Lead Product(s) : Undisclosed

Therapeutic Area : Oncology

Highest Development Status : Undisclosed

Sponsor : BDR Pharmaceuticals

Deal Size : Undisclosed

Deal Type : Agreement

blank